A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
Clinical trial NCT06705504 · COMPLETED
Trial details
- NCT number
- NCT06705504
- Sponsor
- Novartis
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-06-11
- Primary completion
- 2023-11-30
- Enrollment
- 435
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.